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Abstract
Baseline patient and tumor characteristics differentially affected type of death in the MA.17 
placebo-controlled letrozole trial where cardiovascular death was not separately identified. The 
MA.27 trial allowed competing risks analysis of breast cancer (BC), cardiovascular, and other type 
(OT) of death. MA.27 was a phase III adjuvant breast cancer trial of exemestane versus 
anastrozole. Effects of baseline patient and tumor characteristics were tested for whether factors 
were associated with (1) all cause mortality and (2) cause-specific mortality. We also fit step-wise 
forward cause-specific-adjusted models. 7576 women (median age 64 years; 5417 (72 %) < 70 
years and 2159 (28 %) ≥ 70 years) were enrolled and followed for median 4.1 years. The 432 
deaths comprised 187 (43 %) BC, 66 (15 %) cardiovascular, and 179 (41 %) OT. Five baseline 
factors were differentially associated with type of death. Older patients had greater BC (p = 0.03), 
cardiovascular (p < 0.001), and other types (p < 0.001) of mortality. Patients with pre-existing 
cardiovascular history had worse cardiovascular mortality (p < 0.001); those with worse ECOG 
performance status had worse OT mortality (p < 0.001). Patients with T1 tumors (p < 0.001) and 
progesterone receptor positive had less BC mortality (p < 0.001). Fewer BC deaths occurred with 
node-negative disease (p < 0.001), estrogen receptor-positive tumors (p = 0.001), and without 
adjuvant chemotherapy (p = 0.005); worse cardiovascular mortality (p = 0.01), with trastuzumab; 
worse OT mortality, for non-whites (p = 0.03) and without adjuvant radiotherapy (p = 0.003). 
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Overall, 57 % of deaths in MA.27 AI-treated patients were non-breast cancer related. Baseline 
patient and tumor characteristics differentially affected type of death with women 70 or older 
experiencing more non-breast cancer death.
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Introduction
Earlier detection and improved management of breast cancer leads to the prospect that many 
women diagnosed with early breast cancer now will not die from the disease [1–7]. Cuzick 
observed that occurrence of deaths that are not disease related could putatively confound 
efficacy results of adjuvant aromatase inhibitor (AI) trials if the primary endpoint included 
all types of mortality. He recommended that the primary endpoint for AI trials exclude non-
breast cancer death to avoid an apparent dilution of trial therapy effect [7].
We previously found substantive competing risks operative in NCIC clinical trials group 
(CTG) MA.17. MA.17 was a postmenopausal extended endocrine therapy trial, which was a 
placebo-controlled trial of the AI letrozole, after 5 years of tamoxifen therapy [6]. In the 
MA.17 population, 60 % of deaths were not from breast cancer. Those under 70 experienced 
a rate of 48 % non-breast cancer deaths; those 70 or older had 72 %, non-breast cancer 
deaths [6]. We identified differential effects of baseline patient and tumor characteristics on 
type of death. The differences were inferred as indicating potential clinical relevance of the 
competing risks [6]. Cardiovascular deaths were not separately identifiable, although they 
were hypothesized to be a major component of non-cancer death.
To date, MA.27 is the largest trial of AI alone therapy; 7576 patients were randomized to 
two AI, exemestane and anastrozole [9]. The MA.27 trial’s primary endpoint of event-free 
survival (EFS) included all types of death. In two-sided superiority testing, neither 
exemestane nor anastrozole was superior; the hazard ratio (HR) of exemestane to anastrozole 
was 1.02 [95 % confidence interval (CI) 0.87–1.18); p = 0.85] [9]. At the final analysis, 
exemestane- and anastrozole-treated patients also did not experience significantly different 
distant disease-free survival, breast cancer survival, or overall survival. The separate 
identification of MA.27 cardiovascular deaths permitted refined competing risk assessments. 
We examined here whether competing risks of death were operative and potentially relevant 
by way of patient and tumor characteristics differentially affecting type of death.
Methods
Study design
The NCIC CTG MA.27 trial (ClinicalTrials.gov identifier: NCT00066573) was a phase III 
cooperative group study that was a multicenter, multinational, randomized, open-label trial 
approved by health regulatory authorities, and centers’ institutional review boards [9]. MA.
27 originally had a factorial design, with random assignment to exemestane versus 
anastrozole, with or without celecoxib (hypothesized to have an anticancer effect), in 
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postmenopausal women with locally determined hormone receptor-positive primary breast 
cancer. Assignment to celecoxib was discontinued due to reports of cardiac toxicity. Women 
enrolled during celecoxib randomization were included in the comparison of exemestane 
and anastrozole, and stratified by their assignment to celecoxib (yes, no; N = 1622) and 
concomitant prophylactic aspirin use (≤81 mg per day; yes, no; N = 2209). After positive 
results in 2005 of anti-human epidermal growth factor receptor 2 (HER2) therapy in early 
breast cancer, trastuzumab was permitted in women with locally determined HER2-positive 
disease and with protocol amendment to stratify by trastuzumab (yes, no;N = 1915). 
Stratification factors throughout the trial were lymph node status (negative, positive, or 
unknown) and receipt of prior adjuvant chemotherapy (yes, no; N = 7576). After providing 
informed consent, patients were assigned exemestane 25 mg or anastrozole 1 mg daily after 
a morning meal, for 5 years. Participating collaborative groups were NCIC CTG, Eastern 
Cooperative Oncology Group (ECOG), Southwest Oncology Group (SWOG), Cancer and 
Leukemia Group B (CALGB), North Central Cancer Treatment Group (NCCTG), and 
International Breast Cancer Study Group (IBCSG).
MA.27 data were collected, managed, and analyzed by the NCIC CTG. The final analysis 
database was utilized for these analyses. Manuscript writing was undertaken by the authors.
Patient population
MA.27 enrolled postmenopausal women 3–12 weeks following completion of initial 
treatment [9]. Prior hormones, steroids, and raloxifene had to be discontinued ≥3 weeks 
before randomization. Prior treatment with an AI or tamoxifen was not permitted. The 
intention-to-treat (ITT) population comprised 7576 patients: 3789 assigned to exemestane 
and 3787 to anastrozole.
MA.27 study endpoints
The MA.27 primary endpoint was event-free survival (EFS), defined as time from 
randomization to time of loco-regional or distant disease recurrence, new primary breast 
cancer, or death from any cause; censoring was at longest follow-up. Overall survival, 
defined as time from randomization to time of death from any cause, was a secondary 
endpoint of MA.27; censoring was at longest follow-up. We examined here by ITT, the 
multivariate time-to-breast cancer specific, cardiovascular, and other types of death.
Primary objective of competing risks investigation
The primary objective of this investigation was to examine whether there was evidence of 
competing risks operative in the MA.27 trial, by determining whether baseline patient 
characteristics had significantly different effects indicated for different causes of death.
Statistical analysis
Cumulative hazard plots for breast cancer, cardiovascular, and other type mortality were 
used to examine the presence of substantive competing risks that is overlapping time periods 
for different types of death. The indication that substantive competing risks were operative 
then led to examining whether there were differential associations between baseline patient 
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and tumor characteristics and types of death. The Lagakos method was used for this purpose 
[6, 8].
We assumed independent cause-specific risks for death with or from breast cancer, 
cardiovascular death, and death of other type. We tested 2 hypotheses (H1 and H2):
1. H1 A factor does not affect type or time to death, βBreastCancer = βCardiovasular = 
βOtherType = 0, which is tested with a likelihood ratio criterion , 
where βBreastCancer, βCardiovasular, and βOtherType are the cause-specific effects of 
the factor. With rejection of H1, H2 was tested, and
2. H2 A factor has the same effect for all types of death, βBreastCancer = 
βCardiovasular = βOtherType, which is tested with . With rejection of 
H2, a factor was differentially associated with type of death so was assessed 
separately for effects on cause-specific mortality.
We examined the effects of the baseline MA.27 factors: treatment (exemestane, anastrozole); 
age (in years); race (white, other); ECOG performance status (0, other); breast surgery 
(partial, mastectomy); pathologic T (1, other); pathologic N (0, other); estrogen receptor 
status (ER; negative, positive); progesterone receptor status (PgR; negative, positive); 
fractures in past 10 years (no, yes); prior raloxifene use (no, yes); cardiovascular history (no, 
yes); adjuvant radiotherapy (no, yes); adjuvant chemotherapy (no, yes); celecoxib use (no, 
yes); aspirin use (no, yes); and herceptin use (no, yes).
The association of each factor with type of death was examined in a model that included all 
of the factors (the “full-factor” model). Assessment of competing risks by this approach used 
log-normal survival analysis; this assumption was examined for each type of death with 
residual plots versus survival time for those who died.6 For the log-normal analysis, the 
natural logarithm of survival time (t), Y = ln(t), is a linear function, Y = α + Σβj z + σ W, 
where σ is a scale parameter; for the log-normal model, W is the standard normal 
distribution, zj is the jth baseline factor, and βj is the effect of the jth baseline factor on 
mortality.
We also examined the effects of the factors with separate cause-specific (breast cancer, 
cardiovascular, and other types) multivariable analyses by use of the log-normal model. MA. 
27 design was incorporated by always adjusting the cause-specific survival analyses through 
inclusion of treatment and the stratification factors. All other factors were considered in 
step-wise forward regression analyses, with the inclusion of a factor if it had a two-sided p 
value ≤ 0.05 by the likelihood ratio criterion, which has an approximate χ2 distribution with 
1 df (~χ2 with 1 df). We obtained values for the βBreastCancer, βCardiovascular, and βOtherType, 
standard error (SE), and p values, which are based on the assumption that the beta have an 
approximately normal distribution. For comparability of factor effects, graphical depiction 
of the results utilized standardized coefficients, β/SE.
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Results
MA.27 enrolled 7576 patients between June 2, 2003 and July 31, 2008. At the final analysis, 
patients had a median 4.1 years follow-up. Patients had a median age of 64.1 years (Table 1): 
5417 (72 %) < 70 years and 2159 (28 %) ≥ 70 years. Patients were hormone receptor 
positive, either ER positive (+) and/or PgR positive (+).
This report utilized the final analysis follow-up, which is the longest that will ever be 
available for the full MA.27 trial population. Women experienced 432 deaths during this 
period, which comprised 187 (43 %) breast cancer deaths, 66 (15 %) cardiovascular deaths, 
and 179 (41 %) other types of death (A1). Overall, 57 % of deaths in MA.27 patients were 
non-breast cancer related. The three types of death occurred throughout the follow-up period 
(Fig. 1.) so we investigated the operation of these competing risks by way of the effects of 
baseline patient and tumor characteristics on the three types of mortality. The AI therapy, 
exemestane versus anastrozole, was not associated with mortality (p = 0.84). The type of 
deaths experienced by baseline patient characteristics is provided in Table 1.
Five baseline factors were differentially associated with cause of death. Patient 
characteristics with differential associations are presented in Fig. 2. Older age was 
associated with greater breast cancer mortality (p = 0.03), cardiovascular death (p < 0.001), 
and other types of mortality (p < 0.001). Pre-existing cardiovascular history led to worse 
cardiovascular mortality (p < 0.001). Worse ECOG performance status led to worse other 
types of death (p < 0.001). Figure 3 shows mortality differences by tumor characteristics. T1 
tumors were associated with fewer breast cancer deaths (p < 0.001); patients with PgR + 
tumor had less breast cancer mortality (p < 0.001). Assessment of factor effects in step-wise 
modeling of cause-specific mortality (Fig. 4) indicated lower breast cancer mortality with 
node-negative disease (p < 0.001), ER + tumors (p = 0.001), and patients who did not 
receive adjuvant chemotherapy (p = 0.005). There was worse cardiovascular mortality (p = 
0.01) with receipt of trastuzumab. Non-white women had higher other type mortality (p = 
0.03), while lower other type mortality was seen for those receiving adjuvant radiotherapy (p 
= 0.003).
The assumption of a log-normal model was examined in residual plots of differences 
between observed and modeled survival times. Ninety-five percent of residuals would be 
expected to be >−2.0 or < 2.0. The breast cancer residual plot (A2) indicates more small 
residuals, or better fit, than expected for women who died during the first year after accrual 
to MA.27; at median follow-up of 4.1 years, no residuals exceeded 2.0. Residuals indicate 
reasonable support of the log-normal model for cardiovascular (A3) and other types of death 
(A4) with few residuals <−2.0, none >2.0.
Discussion
Cuzick summarized the experience of AI trials, noting that efficacy results could be 
confounded by non-disease-related deaths if the primary endpoint of an AI trial included all 
types of mortality [7]. The primary endpoint for the positive AI trial of extended adjuvant 
trial MA.17 (included in the Cuzick comparison) included only breast cancer death. 
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Meanwhile, MA.27’s primary endpoint included non-breast cancer deaths and there was no 
evidence of a significant treatment effect. In MA.27, we were able to examine whether there 
were differential effects of baseline patient characteristics on the type of death with 
separation of non-breast cancer deaths into cardiovascular or other types of death. We found 
evidence of competing risks in MA.27 with a substantive proportion (57 %) of non-breast 
cancer deaths that was similar to our previous finding of 60 % in MA.17 [6]. Meanwhile, in 
the MA.14 trial testing tamoxifen ± octreotide LAR, 38 % of patients’ deaths were not from 
breast cancer [10].
Mechanistically, simultaneous operation of competing risks would not be important if 
baseline patient and tumor characteristics similarly affected the different types of deaths. We 
hypothesized that differential effects of factors on breast cancer, cardiovascular, and other 
type mortality would indicate evidence of competing risks that were potentially clinically 
relevant and useful for future clinical trial planning. Our approach tested the effects of 
baseline patient and tumor characteristics on cause of death. As in MA.17 [6], we found 
differential effects on type of death, particularly, that older MA.27 patients experienced 
significantly more non-breast cancer death (p < 0.001). Perhaps, not surprisingly, pre-
existing cardiovascular disease was associated with cardiovascular death, worse ECOG 
performance status led to more other type deaths, while patients with lower T stage and 
PgR-positive tumors had less breast cancer mortality.
Additionally, in disease-specific examinations, patients with less lymph node involvement 
and ER positive tumors also had less breast cancer mortality. Patients who had non-
randomized, clinically administered adjuvant chemotherapy had increased breast cancer 
mortality, which is indicative of a more advanced stage. Although based on only a small 
number of patients (N = 74), we observed that those administered trastuzumab experienced 
higher cardiovascular mortality. Non-Caucasians experienced increased other type of 
mortality, which refines the main trial observation that race impacted overall survival [9]. 
Finally, clinical administration of radiotherapy was associated with better other type 
mortality which likely reflects better overall health of those offered radiotherapy.
This competing risks assessment was not protocol specified. The data are those from the 
MA.27 final analysis database, with limited relatively short median 4.1-year follow-up, 
which is the longest uniform follow-up possible due to trial closure. However, MA.27 is to 
date the largest AI alone phase III trial, so the evidence is important. Consistently, patients in 
our AI therapy trials (MA.17 and MA.27) experienced a substantive proportion of non-
breast cancer deaths and increased non-breast cancer death with older age. The breast cancer 
disease attributes of tumor size and hormone receptor status were differentially associated 
with type of mortality, affecting breast cancer death for the MA.27 primary adjuvant trial 
MA.27. Previous cardiovascular disease was differentially associated with type of death, 
through increased unspecified other cause in MA.17 and cardiovascular death in MA.27. 
The introduction of trastuzumab during late accrual phase of MA.27 resulted in only 74 
patients receiving this therapy, so we note with caution the increased cardiovascular 
mortality in conjunction with AI administration. Likewise, the observation of minority 
women having increased other type mortality is reported in the context that only 5 % of MA.
27’s 7576 patients were not white; in the main trial report, race had a significant predictive 
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effect on overall survival (p = 0.02), with minority women on exemestane having 
significantly fewer deaths than those on anastrozole [9]. The differences in trial conduct and 
data limit comparability across trials. The only specific characteristic offered for 
consideration at this time is that a substantive proportion of older patients may be expected 
to die from causes not related to their disease or treatment.
Recognition of the lower breast cancer mortality risk for postmenopausal, hormone receptor-
positive early breast cancer patients raise a cautionary note about the frequent clinical trial 
decision to include non-breast cancer deaths in a trial’s primary endpoint. In clinical 
practice, we think concomitant patient health, particularly of the elderly, should be 
integrated in therapeutic management decisions.
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Fig. 1. 
Cumulative hazard of death from breast cancer, cardiovascular disease, and other type of 
death
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Fig. 2. 
Differential effect of patient characteristics on breast cancer, cardiovascular, and other type 
death. For visual comparability of factor effects, the log-normal model standardized 
coefficients, β/SE ~ N(0,1), are depicted with p values. More negative/positive coefficient 
indicates association with shorter/longer survival that is significant in two-sided test at 5 % 
level if the absolute value exceeds 1.96. Age is assessed in years; cardiovascular history is 
categorized as no versus yes; ECOG performance status is categorized as 0 versus other
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Fig. 3. 
Differential effect of tumor characteristics on breast cancer, cardiovascular, and other type 
death. For visual comparability of factor effects, the log-normal model standardized 
coefficients, β/SE ~ N(0,1), are depicted with p values. More negative/positive coefficient 
indicates association with shorter/longer survival that is significant in two-sided test at 5 % 
level if the absolute value exceeds 1.96. Pathologic T stage is categorized as T1 versus other; 
progesterone receptor (PgR) is categorized as negative versus positive
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Fig. 4. 
Disease-specific effect of patient and tumor characteristics on breast cancer, cardiovascular, 
and other type death. For visual comparability of factor effects, the log-normal model 
standardized coefficients, β/SE ~ N(0,1), are depicted with p values. More negative/positive 
coefficient indicates association with shorter/longer survival that is significant in two-sided 
test at 5 % level if the absolute value exceeds 1.96. Pathologic nodal status is categorized as 
0 versus other; estrogen receptor (ER) is categorized as negative versus positive; adjuvant 
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chemotherapy, herceptin, and adjuvant radiotherapy are categorized as no versus yes; race is 
categorized as white versus other
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